Skip to content

Effects of different doses of fentanyl combined with bupivacaine in spinal anesthesia elective cesarean section: a randomized clinical trial in the Palestinian obstetrics practice

Effects of different doses of fentanyl combined with bupivacaine in spinal anesthesia elective cesarean section: a randomized clinical trial in the Palestinian obstetrics practice

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220430008
Enrollment
190
Registered
2022-04-30
Start date
2018-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean section deliveries Cesarean

Interventions

7.5 mg 1.5 mL dose of 0.5 hyperbaric bupivacaine that was combined with 10 mcg of fentanyl,7.5 mg 1.5 mL dose of 0.5 hyperbaric bupivacaine that was combined with 15 mcg of fentanyl,7.5 mg 1.5 mL dose
G1,G2,Group 3,Group 4

Sponsors

An-Najah National University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1) being at least 18 years old, 2) full-term pregnancy (at least 37 weeks), 3) pregnant with a single fetus, 4) being scheduled for caesarian delivery under spinal anesthesia, 5) American Society of Anesthesiologists (ASA) physical class I and II, and 6) providing written informed consent.

Exclusion criteria

Exclusion criteria: Women who had a history of sensitivity/allergy for local anesthetics and opioids, psychiatric disorders, drug addiction, pregnancy complications, fetal distress, and/or those who could not provide written informed consent were excluded.

Design outcomes

Primary

MeasureTime frame
Blood pressure at 2, 4, and 6 min noninvasive blood pressure monitor,Heart rate at 2, 4, and 6 min pulse oximeter,1)Sensory block latency every min Bromage score

Secondary

MeasureTime frame
duration of analgesia every min VNS

Countries

Palestine

Contacts

Public ContactDirector Alkaissi

An-Najah National University

irb@najah.edu009709234511

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026